ABOUT
3rd Heart Failure Drug Discovery & Development Summit – What Was It About?
The 3rd Heart Failure Drug Discovery & Development Summit returned to tackle key challenges facing preclinical heart failure drug development by uniting 50+ biopharma and delving into targeting, stratifying and treating cardiomyopathies with greater precision.
What You Could Have Experienced:
Elevating your understanding of precision approaches to heart failure with Bayer & Tenaya
Unearthing developments in accelerating the translatability for heart failure disease modelling with Pfizer & Novo Nordisk
Staying ahead of the curve on developments in the intersection of aging biology and heart failure with Regeneron
Delving into novel biology from non-coding RNAs to gene therapy and small molecules with LEXEO, Cytokinetics & Cardior
Increasing your understanding on optimal stratification of heart failure with Novartis
Who Was in The Room?
This summit stood as the hub of knowledge, showcasing the latest in developments in the preclinical heart failure drug development. Together with 50+ experts, yourself and your team could have been immersed in cutting-edge cardiac drug development from discovery to target validation.
What Your Peers Have to Say About The 2024 Summit
‘’Exciting agenda of high relevance to precision cardiology’’
Senior Director, Bayer
Who's Spoke?
